ZERAMAL

This brand name is authorized in Nigeria.

Active ingredients

The drug ZERAMAL contains a combination of these active pharmaceutical ingredients (APIs):

1	Artemether UNII C7D6T3H22J - ARTEMETHER
	Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
	Read more about Artemether
2	Lumefantrine UNII F38R0JR742 - LUMEFANTRINE
	Read more about Lumefantrine

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-6531	Tablet	Zeramal QS Tablet TAB 80 mg; 480 mg 1 x 6's (in Alu/PVC blister)	Film-coated Tablet. Yellow colored, round shaped, biconvex film-coated tablet with a breakline on one side. The breakline is only to facilitate breaking for ease of swallowing and not to divide into equal doses	24/11/2022
A4-8042	Tablet	Zeramal 20/120 TAB 20 mg; 120 mg 1 x 24's (in Alu-PVC blister)	Tablet. Yellow colour, circular/round shape, flat and have an embossing of ‘ZERAMAL’ at one side and a breakline on another side	22/11/2024
B4-1802	Tablet	Zeramal TS Tablets TAB 60 mg; 360 mg 1 x 6's (in Alu/PVC blister)	Tablet. Yellow-coloured, circular/round shape, biconvex and one side have an embossing of ‘ZERAMAL TS’ and plain on another side	25/09/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BF01	Artemether and lumefantrine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-6531, A4-8042, B4-1802